Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis

AIM: The role of tumor burden (TB) for patients with non-small cell lung cancer (NSCLC) receiving immunotherapy is still unknown. The aim of this analysis was to analyze the prognostic value of TB in a real-world sample of advanced NSCLC patients. METHODS: Sixty-five consecutive patients with advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenci, Edoardo, Marcantognini, Giulia, Cognigni, Valeria, Lupi, Alessio, Rinaldi, Silvia, Cantini, Luca, Fiordoliva, Ilaria, Carloni, Anna Lisa, Rocchi, Marco, Zuccatosta, Lina, Gasparini, Stefano, Berardi, Rossana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400786/
https://www.ncbi.nlm.nih.gov/pubmed/36046436
http://dx.doi.org/10.37349/etat.2021.00043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400786/
https://www.ncbi.nlm.nih.gov/pubmed/36046436
http://dx.doi.org/10.37349/etat.2021.00043

Ejemplares similares